| the use of primaquine in malaria infected patients with red cell glucose-6-phosphate dehydrogenase (g6pd) deficiency in myanmar. | 32 subjects with plasmodium falciparum gametocytes, and 31 cases with plasmodium vivax infection from two military hospitals (lashio, mandalay) were treated with quinine 600 mg three times a day for 7 days followed by primaquine 45 mg single dose for gametocytes and 45 mg weekly x 8 weeks for vivax malaria. although screening of red cell glucose-6-phosphate dehydrogenase (g6pd) was done prior to primaquine treatment, g6pd deficient subjects were not excluded from the trial. 20 patients hemizygou ... | 1994 | 7667719 |
| comparison of the antibody responses to plasmodium vivax and plasmodium falciparum antigens in residents of mandalay, myanmar. | abstract: | 2011 | 21819610 |
| genetic variations of the dihydrofolate reductase gene of plasmodium vivax in mandalay division, myanmar. | dihydrofolate reductase (dhfr; ec1.5.1.3) is a known target enzyme for antifolate agents, which are used as alternative chemotherapeutics for chloroquine-resistant malaria. mutations in the dhfr gene of plasmodium vivax are thought to be associated with resistance to the antifolate drugs. in this study, we have analyzed genetic variations in the dhfr genes of clinical isolates of p. vivax (n=21) in myanmar, to monitor antifolate resistance in this country. sequence variations within the entire d ... | 2005 | 15924223 |